EU-US mutual recognition extends with Portugal added to roster

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Evgeny Gromov)
(Image: Getty/Evgeny Gromov)

Related tags: Eu, Us, Fda, Gmp

With the US recognising Portugal’s ability to carry out GMP inspections, 15 countries are now part of the mutual recognition agreement between the EU and the US.

In waves, the US Food and Drug Administration (FDA) has been revealing the European Union (EU) countries that meet its good manufacturing practice (GMP) inspections standards.

The mutual recognition agreement discussions between the US and EU had steadily moved closer to reaching a deal, with a series of smaller understandings​, before the official announcement on November 1, 2017, that the two countries would officially begin the process​.

The mutual recognition arrangement sees the workload of both agencies reduced, as the review of facilities then do not need to be replicated once any member of the agreement has carried out GMP inspections.

The process began with eight EU countries but has slowly increased in number and, with the addition of Portugal, now includes 15 countries that the FDA recognises as having the same standards as those held during its own inspections.

The planned timeline of the understanding sees a deadline of July 15, 2019, for all EU countries to be inducted into the mutual recognition agreement.

In a statement, the EMA explained, “The agreement is underpinned by robust evidence on both sides of the Atlantic that the EU and the US have comparable regulatory and procedural frameworks for inspections of manufacturers of human medicines.”

Beyond the EU-US agreement, there is also a move by the EU towards closer ties to Japan’s Pharmaceuticals and Medical Devices Agency. In the most recent development of this relation, in July of this year, the EU and Japan agreed to extend mutual recognition​ to biologics and active pharmaceutical ingredients.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars